CD8A and cancer: The routine clinical workup of these patients was implemented with the investigation of CD8 T-cell responses against EBV and CMV antigens and “universal” TAAs, the assessment of viral reactivations and quantification of circulating TERT mRNA in plasma as potential source of risk-predictive biomarkers for a broad spectrum of cancers, such as those occurring in SOT recipients.